Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Keros Therapeutics Inc.

    NASDAQ: KROS · Real-Time Price · USD
    13.65
    -0.01 (-0.07%)
    At close: Jun 17, 2025, 10:21 AM

    Keros Therapeutics Statistics

    Share Statistics

    Keros Therapeutics has 40.62M shares outstanding. The number of shares has increased by 12.41% in one year.

    Shares Outstanding

    n/a
    		 40.62M

    Shares Change (YoY)

    n/a
    		 12.41%

    Shares Change (QoQ)

    n/a
    		 0.13%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 33.61M

    Failed to Deliver (FTD) Shares

    n/a
    		 458

    FTD / Avg. Volume

    n/a
    		 0.05%

    Short Selling Information

    The latest short interest is 5.31M, so 13.06% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 5.31M

    Short % of Shares Out

    n/a
    		 13.06%

    Short % of Float

    n/a
    		 20.47%

    Short Ratio (days to cover)

    n/a
    		 9.2

    Valuation Ratios

    The PE ratio is -3.16 and the forward PE ratio is -3.2. Keros Therapeutics's PEG ratio is 0.82.

    PE Ratio

    n/a
    		 -3.16

    Forward PE

    n/a
    		 -3.2

    PS Ratio

    n/a
    		 166.94

    Forward PS

    n/a
    		 4.1

    PB Ratio

    n/a
    		 1.04

    P/FCF Ratio

    n/a
    		 -3.64

    PEG Ratio

    n/a
    		 0.82
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Keros Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 21.45, with a Debt / Equity ratio of 0.03.

    Current Ratio

    n/a
    		 21.45

    Quick Ratio

    n/a
    		 21.45

    Debt / Equity

    n/a
    		 0.03

    Debt / EBITDA

    n/a
    		 -0.1

    Debt / FCF

    n/a
    		 -0.12

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $21,779.14

    Profits Per Employee

    n/a
    		 $-1,149,404.91

    Employee Count

    n/a
    		 163

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 300K

    Effective Tax Rate

    n/a
    		 -0.16%

    Stock Price Statistics

    The stock price has increased by -69.43% in the last 52 weeks. The beta is 1.29, so Keros Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.29

    52-Week Price Change

    n/a
    		 -69.43%

    50-Day Moving Average

    n/a
    		 13.7

    200-Day Moving Average

    n/a
    		 29.87

    Relative Strength Index (RSI)

    n/a
    		 44.37

    Average Volume (20 Days)

    n/a
    		 983,365

    Income Statement

    In the last 12 months, Keros Therapeutics had revenue of 3.55M and earned -187.35M in profits. Earnings per share was -5.

    Revenue

    n/a
    		 3.55M

    Gross Profit

    n/a
    		 2.32M

    Operating Income

    n/a
    		 -210.83M

    Net Income

    n/a
    		 -187.35M

    EBITDA

    n/a
    		 -185.82M

    EBIT

    n/a
    		 -187.05M

    Earnings Per Share (EPS)

    n/a
    		 -5
    Full Income Statement

    Balance Sheet

    The company has 559.93M in cash and 18.86M in debt, giving a net cash position of 541.07M.

    Cash & Cash Equivalents

    n/a
    		 559.93M

    Total Debt

    n/a
    		 18.86M

    Net Cash

    n/a
    		 541.07M

    Retained Earnings

    n/a
    		 -568.78M

    Total Assets

    n/a
    		 784.56M

    Working Capital

    n/a
    		 720.13M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -160.87M and capital expenditures -1.93M, giving a free cash flow of -162.8M.

    Operating Cash Flow

    n/a
    		 -160.87M

    Capital Expenditures

    n/a
    		 -1.93M

    Free Cash Flow

    n/a
    		 -162.8M

    FCF Per Share

    n/a
    		 -4.35
    Full Cash Flow Statement

    Margins

    Gross margin is 65.38%, with operating and profit margins of -5938.96% and -5277.55%.

    Gross Margin

    n/a
    		 65.38%

    Operating Margin

    n/a
    		 -5938.96%

    Pretax Margin

    n/a
    		 -5269.1%

    Profit Margin

    n/a
    		 -5277.55%

    EBITDA Margin

    n/a
    		 -5234.48%

    EBIT Margin

    n/a
    		 -5938.96%

    FCF Margin

    n/a
    		 -4585.92%

    Dividends & Yields

    KROS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for KROS is $24, which is 76.1% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $24

    Price Target Difference

    n/a
    		 76.1%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 13
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 6.77

    Piotroski F-Score

    n/a
    		 7

    Add to Watchlist